From Alchemy to IPO

This weekend I´m reading Cynthia Robbins-Roth´s (Ph.D.) book (ISBN 0-7382-0253-3).
Companies like Genentech, Amgen, Genzyme, and their foundation stories are key to understand the biotech industry beginnings.

The book addresses the importance (for biotech) of timing creation and seizure, based by a converged business and scientific vision of a better future. Timing marked by an appropriate tax policy, a long term investment perspective, enough availability of critical mass, and fairly willing to take a chance (among others).

I wish I had read this book before my meeting with Dr. Carlos Barbas III(Ph.D.) at Scripps Institute in La Jolla, Ca., when trying to figure out how to bring a piece of the biotech business to Baja California (When managing COPREEN).